The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.

A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.

The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C.sub.3-C.sub.8 carboxylic acids, their physiologically tolerable salts and/or esters with C.sub.1-C.sub.8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents.

A nutritional product for improving performance during physical activity and a method of using the nutritional product to improve performance during activity. The nutritional product contains Rhodiola root extract, French pine extract, Pulsatilla vulgaris extract, ginger extract, yohimbe extract, Ginseng extract, Coleus forskohlii extract, vitamin B12, red beet extract, L-Arginine NO3, tongkat ali, a combination of Fenugreek fenugreek A and Fenugreek fenugreek B, and Tribulus terrestris extract. Also described are methods for improving a user's physical activity performance employing the nutritional products.

Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

The present disclosure provides techniques for producing whey protein nano-emulsions from cannabis extracts. An emulsion prepared using an embodiment of a method of the invention can be subject to further processing with which to convert the emulsion (or a component thereof) into one or more consumables.

Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers such as urothelial, bladder, and kidney cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.